Background: The use of prosthetic grafts in the treatment of intermittent claudication is still a controversy. Prosthetic bypass for this usually benign condition may in some cases lead to a graft ...

SUNNYVALE, Calif.--(BUSINESS WIRE)--PQ Bypass, Inc., today announced it has received conditional approval of its investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) ...

Please provide your email address to receive an email when new articles are posted on . PQ Bypass Inc. announced in a press release that it has received conditional approval of its investigational ...

PQ Bypass, Inc. is a Silicon Valley-based medical device company developing the DETOUR procedure for percutaneous femoropopliteal bypass. Our proprietary DETOUR™ System is a physician-driven ...

In patients with femoropopliteal artery disease, endovascular therapy produces fewer early complications, but surgery holds a longer-term edge in fewer amputations and better overall survival, ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — A percutaneous femoropopliteal bypass system appears to be feasible, according to interim results of ...

EATONTOWN, N.J.--(BUSINESS WIRE)-- Flexible Stenting Solutions Inc. announced today the successful treatment of the first two patients enrolled in the OPEN (Evaluation of Safety and Efficacy of the ...

Pq Bypass Inc. received breakthrough device designation from the FDA for its Detour system, the first to permit fully percutaneous femoropopliteal bypass to treat extremely long, complex blockages in ...

MIAMI BEACH, FLA.—Patients with femoropopliteal lesions who receive 12 months of cilostazol after endovascular stenting experience restenosis rates 50% lower than those in patients who do not receive ...

The mean age of the patients was 68 years (range, 50-88 years), 72 years for women and 67 years for men. This difference is significant (p < 0.01). There was no difference in the distribution of ...